By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Sequenom today with an Outperform rating, citing the commercial potential of the San Diego-based company's T21 molecular diagnostics test.

Analyst Brian Weinstein estimated in a research note that Sequenom would have 2011 revenues of $54.8 million and 2012 revenues of $78.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.